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No Effect of a Whey Growth Factor Extract during Resistance Training on
Strength, Body Composition, or Hypertrophic Gene Expression in ResistanceTrained Young Men
Michael J. Dale, Alison M. Coates, Peter R.C. Howe, Grant R. Tomkinson, Matthew T. Haren, Andrew
Brown, Marissa Caldow, David Cameron-Smith, Jonathan D. Buckley
ABSTRACT
Growth factors can be isolated from bovine milk to form a whey growth factor extract (WGFE). This
study examined whether WGFE promoted activation of the AKT/mTOR pathway enabling increased lean
tissue mass and strength in resistance trained men. Forty six men with >6 months of resistance training
(RT) experience performed 12 weeks of RT. Participants consumed 20 g/day of whey protein and were
randomised to receive either 1.6 g WGFE/day (WGFE; n = 22) or 1.6 g cellulose/day (control, CONT; n =
24). The primary outcome was leg press one-repetition maximum (LP1-RM) which was assessed at
baseline, 6 and 12 weeks. At baseline and 12 weeks body composition was assessed by dual energy x-ray
absorptiometry, and muscle protein synthesis and gene expression were assessed (vastus lateralis biopsy)
in a sub-sample (WGFE n = 10, CONT n = 10) pre- and 3 hr post-training. RT increased LP1-RM
(+34.9%) and lean tissue mass (+2.3%; p < 0.05) with no difference between treatments (p > 0.48,
treatment x time). Post-exercise P70s6k phosphorylation increased acutely, FOXO3a phosphorylation was
unaltered. There were no differences in kinase signalling or gene expression between treatments.
Compared with CONT, WGFE did not result in greater increases in lean tissue mass or strength in
experienced resistance trained men.
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INTRODUCTION
Resistance training can increase strength and skeletal muscle mass, but the adaptive responses can be
enhanced through an increased protein intake, and in particular an increased intake of whey protein (Cribb
et al., 2006; Miller et al., 2014). Whey protein is a rich source of amino acids including branched-chain
amino acids (BCAA) that are critical for increasing muscle protein synthesis (Ha and Zemel, 2003) and
also contains small amounts of growth factors which may contribute to increases in muscle size and
strength (Walzem et al., 2002). Other dairy foods that are rich in growth factors have also been shown to
improve muscular adaptations to resistance training, such as bovine colostrum. Bovine colostrum is the
first milk produced by cows after calving and contains high concentrations of growth factors (Francis et
al., 1988). Bovine colostrum has been shown to increase lean tissue mass (Antonio et al., 2001) and
muscular power (Buckley et al., 2003) when consumed during resistance exercise training. However, the
availability of colostrum is limited relative to that of normal cow’s milk. This has led to the development
of chromatography technologies to extract growth factors from milk and/or whey (Francis et al., 1995) to
produce growth factor-rich products to potentially increase muscular adaptations to exercise training.
Whey Growth Factor Extract (WGFE) is a concentrated protein source consisting primarily of
Lactoperoxidase (62%) and Lactoferrin (16%) proteins, but is also enriched in other growth factors such
as insulin-like growth factors (Collier et al., 1991) that are naturally present in milk at low concentrations.
A preliminary study using untrained volunteers indicated that WGFE supplementation (2 g/day) during 12
weeks of resistance training resulted in ~35% greater increase in leg strength (Carey et al., 2006;
Crittenden et al., 2009). However, whether WGFE enhances strength increases in individuals who are
already resistance trained is unclear.

Muscle hypertrophy in response to resistance training requires activation of the AKT/mTOR pathway
(Philp et al., 2011), which can be activated by IGF-1 (Rommel et al., 2001). This pathway activates the
ribosomal complex and initiates translation downstream of the kinase P70s6k, increasing the rate of new
protein synthesis. Simultaneously intense exercise may stimulate the ubiquitin proteasome pathway and
the induction of muscle-specific E3-ubiquitin ligases, atrogin-1 and muscle RING finger-1 (MuRF1)
which promote muscle turnover (Rahbek et al., 2015; Stefanetti et al., 2014). This is achieved by the E3ubiquitin ligases regulating transcription of the Forkhead Box (FOXO) proteins, including the FOXO3
isoform (Okamoto et al., 2011). There is evidence that the ingestion of dairy protein can influence the
mTOR pathway (Mitchell et al., 2015), possibly due to its IGF-1 content (Rommel et al., 2001), but not
the FOXO pathway (Stefanetti et al., 2014). Studies are yet to address the actions of WGFE on these
pathways.
The aim of this study was to examine the effect of supplementation with WGFE on muscle strength, body
composition and molecular pathways controlling skeletal muscle hypertrophy in men with a history of
resistance exercise training. We hypothesised that WGFE would promote activation of the AKT/mTOR
pathway and thus increase muscle anabolism enabling greater increases in lean tissue mass and strength.
METHODS
This study used a randomised, double-blind, placebo-controlled parallel design. All participants undertook
a 12-week progressive resistance exercise training program and were allocated to concurrent daily
consumption of 20 g of whey protein isolate together with 1.6 g of cellulose (CONT n = 24) or 1.6 g of
WGFE (n = 22). A dose of 1.6 g/day, rather than the 2 g/day used in the preliminary study (Carey et al.,
2006; Crittenden et al., 2009), was chosen to improve the commercial viability of the product as a
supplement by reducing cost per effective dose. Ten participants from each group underwent vastus
lateralis muscle biopsies pre- and post-training at baseline and after the 12-week training program. To
account for potential confounding effects of differences in baseline muscle strength participants were
allocated to treatment via minimisation (Altman and Bland, 2005) based upon peak isometric knee
extension torque data collected during a pre-intervention familiarisation session. Participants were further
stratified on the basis of training experience and age. Assessments at baseline and after the 12-week
training program were performed at the same time of day to control for circadian variation. A diagram of
the study protocol is provided in Figure 1. This study was approved by the Human Research Ethics
Committee of the University of South Australia and conformed to the standards set by the Declaration of
Helsinki. All participants provided written informed consent prior to participating.

Figure 1. Diagram of study protocol. WGFE – Whey growth factor extract. WPI – whey protein isolate. DXA – dual
energy x-ray absorptiometry. RT – resistance training. KE – knee extensor. LP-1RM – leg press one repetition maximum.
WFR – weighed food record.

Participants
Adult males aged 18-30 years who had been participating in regular (>2 sessions per week) resistance
exercise training for at least six months immediately prior to the study were recruited via public
advertisement. All participants reported being free from current or prior musculoskeletal injury which
would prevent them from undertaking the training required for the study. Prospective participants were
excluded if they were: (a) smokers or had recently (within the previous 6 months) quit smoking; (b)
engaged in other athletic training that might confound the outcomes of the present study; (c) consumed
prescription medication; (d) were allergic to/sensitive to/intolerant of dairy proteins or lactose; or (e) had
recently (within the past 6 months) taken any form of supplement intended to increase physical
performance or enhance recovery. All potential participants were administered the Sports Medicine
Australia pre-exercise screening questionnaire (Sports Medicine Australia, 2005), with only those
classified as low risk accepted into the study.
Supplements
All study supplements were commercially available products (Murray Goulbum Co-Operative Co Ltd,
Melbourne, Australia). The protein and growth factor composition of the WGFE supplement is provided
in Table 1. Both WGFE and CONT groups consumed 20 g of whey protein isolate powder daily, mixed
with 250 mL of water. Additionally both groups consumed four capsules each morning. Those randomised
to the WGFE group consumed capsules each containing 400 mg of whey growth factor extract (i.e. 1.6 g
dose; Catalyst, Murray Goulbum, Parkville, Australia), whilst each CONT capsule contained 400 mg of
cellulose (i.e. 1.6 g dose). The capsules were identical in appearance. Supplements were consumed
immediately upon rising on non-training days and immediately after training on training days. Compliance
with supplementation was determined by capsule counting.
Table 1. Composition of whey growth factor extract.
Compositional components
Content
Protein
Total protein content (% w/w)*

97.5

Lactoperoxidase (% w/w)*

41.2

Lactoferrin (% w/w)*

23.8

RNase 5 (% w/w) †

8

IgG (% w/w)*

6.7

IgA (% w/w) ††

6.1

RNase 4 (% w/w) †

4

Growth factors
Transforming growth factor-β2 (ng/mg protein) ††

45.8

Insulin-like growth factor I (ng/mg protein) ††

27.1

Insulin-like growth factor II (ng/mg protein) ††

20

Platelet derived growth factor (ng/mg protein) ††

4

Betacellulin (ng/mg protein) ††

.4

Fibroblast growth factor 1 (ng/mg protein) ††
.4
* Analysis performed by *Dairy Technical Services Ltd, Melbourne, Australia
†Murray Goulburn Co-operative Ltd, Melbourne, Australia
††TGR Biosciences, Adelaide, Australia.

Anthropometry and body composition measures
At baseline height was measured using a stadiometer (SECA, Hamburg). Body mass was measured using
digital scales (Tanita Ultimate Scale, Tokyo) at baseline and after 6 and 12 weeks and mid-thigh girth was
measured using a tape (Lufkin, Apex Tool Group, Maryland) following International Society for the
Advancement of Kinanthropometry (ISAK) protocols (Marfell-Jones et al., 2007). Body composition was

assessed at Weeks 0 and 12 using dual-energy x-ray absorptiometry (DXA, Lunar Prodigy, General
Electric, Madison, WI, USA, using enCORE 2003 software version 7.52.002), with whole body and
regional (right thigh) non-bone lean and fat tissue mass determined. The thigh segment assessed in the
regional analysis was defined as the area bordered distally by a line passing through the medial and lateral
joint spaces of the knee, parallel to the tibial plateau and proximally by a line passing immediately distal to
the most inferior point of the ischial tuberosity and immediately proximal to the superior border of the
greater trochanter. Medial and lateral borders included all lower limb soft tissue falling between the
proximal and distal boundaries. Test-retest reliability for data extraction was assessed on baseline DXA
scans from all 46 subjects. Region of interest data were extracted from the same scan on separate days,
and reliability of extraction was excellent for both lean tissue mass (ICC ± 95%CI: 1.000 ± 0.001) and fat
tissue mass (ICC ± 95%CI: 1.000 ± 0.001).
Strength measures
Maximal isometric torque of the right knee extensors was assessed using an isokinetic dynamometer
(Biodex System 4, Biodex Medical Systems Inc, Shirley, NY). Participants were positioned on the
dynamometer with the knee joint flexed to 90° and the axis of rotation of the knee joint aligned with the
axis of rotation of the lever arm of the dynamometer. The lever arm of the dynamometer was strapped to
the participants’ ankle at 3 cm above the medial malleolus. Seat position data (seat pan depth, seat rail
location, lever arm length) were recorded to enable replication of position for subsequent testing. Three
sub-maximal warm-up efforts of 5 seconds duration were performed with a 1-minute rest between efforts.
After a 2-minute rest, three maximal 5-second isometric efforts were performed with a 1-minute rest
between. Test-retest reliability was assessed using data from two testing sessions separated by 1-2 weeks
on all 46 subjects. Reliability for maximal isometric torque was excellent (ICC ± 95%CI: 0.92 ± 0.05).
One-repetition maximum (1RM) testing was performed for incline leg press following American College
of Sports Medicine (ACSM) guidelines (American College of Sports Medicine, 2006).
Non-biopsy participants began training 2-3 days after baseline testing, to allow for recovery from the 1RM
testing procedure. Participants undergoing biopsies began training on the day of their biopsy, which
occurred 4-7 days after baseline testing.
Resistance training intervention
Participants were familiarised with the strength testing protocols and the resistance training program prior
to commencement of testing. Each participant underwent a 2-hour familiarisation session to ensure correct
technique for all exercises comprising the testing and training program. The resistance training program
consisted of a whole-body, non-periodised, progressive program designed to improve strength and
hypertrophy. Participants trained at the research facility gymnasium three times per week with 24-72 hours
between training sessions. The following exercises were performed in order: bench press, smith machine
hack squat, lat pulldown, incline leg press, weighted dip, preacher bench biceps curl, seated row, seated
calf raise, and sit-ups. All exercises (except sit-ups) were performed using custom-made resistance
equipment (Maxim, Adelaide, Australia).
Three sets of 12 repetitions per exercise were attempted (except for the sit-ups where three sets of 20
repetitions were attempted), with a 1-minute rest period between sets and a 2-minute rest period between
exercises. Lifting was continued until concentric failure or the 12 or 20 repetition target was reached. The
number of repetitions per set was recorded by each participant in a training diary, with participantselected increases (typically 2.5 to 10.0 kg, dependent upon the exercise) occurring when the participant
could successfully perform three sets of 12 repetitions at the target resistance. Progression for the
unweighted sit-ups task occurred through increases in the numbers of repetitions, with a 2-repetition

increase occurring when three sets of 20 repetitions could be successfully performed. The total volume of
training per treatment group was quantified as the total number of exercises x number of sets x number of
repetitions x resistance (kg), and was expressed per training session. All training sessions were supervised
in order to ensure correct technique was used and compliance with the training program.
Muscle biopsy
A sub-population from each treatment group (WGFE and CONT, n=10 per group) underwent muscle
biopsies at 1 hour pre- and 3 hours post-training at Weeks 0 and 12. Muscle tissue (~100 mg) from the
right vastus lateralis muscle ~15 cm above the patella was harvested by a registered Medical Practitioner
using the percutaneous biopsy technique (Bergstrom) modified to include suction under a 1% lignocaine
local anaesthetic. Tissue was immediately visualised at x10 magnification, blotted free of blood and
cleaned of any connective tissue, and then snap frozen in liquid nitrogen and stored at -80° C. Posttraining
biopsy samples were collected through the same incision but with the biopsy needle angled inferiorly and
medially to avoid the pre-training biopsy site, with different incisions at Week 0 and 12.
Western blotting
Tissue samples (10 mg) were homogenised in cell lysis buffer following the manufacturer’s instructions
(Biorad, Hercules, CA) using a tissue disruptor for 20 seconds at a speed setting of 5.5 (FastPrep, ThermoFisher Scientific, Australia). The homogenate was frozen at -80° C for 10 min then rotated at 4° C for 1
hour. The lysate was centrifuged at 13000 rpm at 4° C for 10 minutes and the supernatant collected.
Protein concentration was determined using the BCA protein assay kit, following the manufacturer’s
instructions (Thermo-Fisher Scientific, Australia). Protein (50 pg) was separated by 8% SDS-PAGE. The
proteins were transferred onto a nitrocellulose membrane and blocked in 5% bovine serum albumin (BSA)
in Tris Buffered Saline with 0.1% Tween 20 (TBST) for 2 hours at room temperature. Primary antibodies,
diluted in blocking buffer (1:1000) were applied and incubated overnight at 4° C; p-mTOR (Ser2448),
mTOR, p-p70S6K (Thr389), p70S6K, p-Akt (Ser473), Akt, p- FOXO3a (Ser253), and FOXO3a (Cell
Signalling Technology Inc., Danvers, MA). Membranes were washed six times for 5 minutes with TBST
and incubated for 1 hour at room temperature with corresponding HRP-conjugated antibodies; rabbit
(Merck Biosciences, Australia). Membranes were then washed six times for 5 minutes with TBST and
proteins were detected by enhanced chemiluminescence (Western Lighting Chemiluminescence Reagent
Plus, Perkin Elmer Lifesciences, Boston, MA). The density of the bands was quantified using a Kodak
Image Station (Model: 440CF, Eastman Kodak Company, USA) and quantified by densitometry software
(Kodak 1D 3.5). Membranes were stripped using Restore™ Western Blot Stripping Buffer (ThermoFisher Scientific, Australia) for 30 minutes before being re-probed with the total antibody, to confirm that
changes observed in phosphorylation were not due to changes in total protein levels.
Reverse transcription polymerase chain reaction (RT-PCR)
RNA was extracted from the vastus lateralis biopsies (5-7 mg) using the Totally RNA kit (Applied
Biosystems, Foster City, CA). RNA quality and concentration were determined (Nanodrop 1000, ThermoFisher Scientific, Australia). First-strand cDNA was generated using 0.5 pg of total RNA via the RNA-tocDNA kit (Applied Biosystems, Foster City, CA). RT-PCR was performed in triplicate using the ABI7500
sequence detection system (Applied Biosystems, Foster City, CA), with reaction volumes of 14 pl,
containing Power SYBR Green (Applied Biosystems, Foster City, CA), forward and reverse primers and
cDNA template (1.25 ng/ul). Data were analysed using a comparative critical threshold (Ct) method where
the amount of target was normalised to the amount of endogenous control, relative to control value given
by 2-AACt (Applied Biosystems, Foster City, CA). The efficacy of Cyclophilin, 18S, TBP and GAPDH as
endogenous controls was examined using the equation 2-ACt. GAPDH gene expression showed no change

in response to exercise (data not shown) and was therefore used for normalisation of the target gene.
Dietary intake
Food intakes were recorded at baseline, Week 6 and Week 12 using 3-day weighed food records which
included at least one weekend day. Energy intake, macro and micronutrient profiles were calculated using
Foodworks® Nutritional software (Xyris Software, Pty Ltd, Highgate Hill, Queensland; Australia).
Statistical analysis
Data were only analysed for participants who completed the intervention. Data are presented throughout as
means±standard deviation (SD) unless otherwise indicated. Student’s t-tests were used to compare group
means at baseline. To determine the effects of the treatment, time of measurement and their interactions on
the outcome measures, data were analysed using a Random Effects Model (REM). Parameters were
established using restricted maximum likelihood (REML) rather than maximum likelihood (ML) due to
the relatively small sample. Post-hoc testing was performed to localise the main effects, where relevant,
using sequential Bonferroni corrected t-tests. The Pearson correlation was used to determine relationships
between parameters. Due to the potential for baseline strength to influence the magnitude of increase in
strength participants were stratified on the basis of baseline leg strength (isometric knee extension
strength) and secondary analysis was undertaken to evaluate whether there were differences in strength
gains in different tertiles of baseline strength. NCSS version 7.0 (NCSS, Kaysville, USA) or SPSS version
20 (IBM Corp, New York, USA) was used for all statistical analysis. The level of significance was set at a
of 0.05.
RESULTS
Participants
A total of 93 prospective participants were screened for inclusion. Sixty eight participants were enrolled
into the study and completed baseline testing, with 46 completing the study (Figure 2). These participants
were highly compliant to the training (completing 92% of scheduled training sessions) and the supplement
protocols (96% of supplement capsules consumed). At baseline the CONT and WGFE groups were well
balanced by age, height, mass and training experience (Table 2).

Figure 2. CONSORT diagram indicating participant flow through study.

Table 2. Participant characteristics at baseline. Data are shown as mean (±standard deviation).
CONT group(n = 34)
WGFE group(n = 33)
Age, yr
21.8 (2.9)
21.9 (3.2)
Height, m
1.8 (.1)
1.8 (.1)
Mass, kg
75.0 (9.8)
76.4 (11.1)
TR experience, months
20.6 (18.0)
28.6 (34.3)

TR = Training, CONT = Control, WGFE = Whey Growth Factor Extract (WGFE)

Leg strength and training load
Data for leg strength and loads lifted during training are presented in Table 3. Both CONT and WGFE
increased isometric knee extensor strength and leg press strength (LP1-RM; primary outcome) during the
study period, but there was no difference between groups (p > 0.85, treatment x time).
Table 3. Leg strength and training loads. Values are mean (±SD).
CONT group (n = 24)
WGFE group (n = 22)
Week 0
Week 6
Week 12
Week 0
Week 6
Week 12
Incline leg press 1RM, kg
280(46)
354(65)*
373(65)*†
289(56)
364(48)*
389(52)*†
Maximum Isometric knee-extensor Force, Nm
295(64)
306(63)*
314(67)*†
285(47)
297(45)*
301(51)*†
Load lifted per training session, kg
19421 (3386)
20064 (4457)
19104 (3253)
19072 (4798)
CONT = Control, WGFE = Whey Growth Factor Extract.
*significantly different from Week 0 (p < 0.05)
†significantly different from Week 6 (p < 0.05).

Secondary analysis of incline leg press strength data showed that baseline strength was inversely
correlated with the change in strength by Week 12 in the WGFE group (r = -0.49; P=0.03) but not in the
CONT group (r = -0.05; p = 0.80). Accordingly, for participants in the lowest tertile of leg press strength
at baseline there was a significantly greater increase in leg press strength in those who consumed WGFE
compared with CONT (p = 0.002; treatment effect).
Anthropometry and body composition
Data for anthropometric and body composition measures are reported in Table 4. Body mass increased
during the study period (p < 0.05 for time), with no difference between treatments (p = 0.98, treatment x
time). The body mass increases were driven by increases in non-bone lean tissue mass which also
increased (p < 0.001 for time), with no difference between treatments (p = 0.85, treatment x time).
Table 4. Anthropometric and body composition measures. Values are mean (±SD).
CONT group (n = 24)
WGFE group (n = 22)
Week 0
Week 6
Week 12
Week 0
Week 6
Week 12
Body Mass, kg
75.0 (9.8
75.9 (9.5)
76.1 (9.3)*
76.4 (11.1)
77.1 (10.3)
77.4 (10.8)*
Whole Body non-bone Lean Tissue Mass, kg
58.7 (5.7)
60.0 (5.8)*
60.0 (6.9)
61.3 (7.0)*
Whole Body Fat Mass, kg
12.2 (4.6)
12.2 (4.7)
12.5 (6.8)
12.3 (6.0)
Thigh non-bone Lean Tissue Mass, kg
6.3 (.9)
6.5 (.9)*
6.6 (.9)
6.8 (1.0)*
Thigh Fat Mass, kg
2.0 (.7)
2.0 (.8)
2.0 (.1)
2.1 (.1)
Thigh Girth, cm
52.2 (3.8)
53.2 (3.7)*
53.4 (3.5)*
52.9 (4.5)
53.8 (4.0)*
53.8 (4.0)*
CONT = Control, WGFE = Whey Growth Factor Extract.
*significantly different from Week 0 (p < 0.05)
†significantly different from week 6 (p < 0.05).

Regional analysis of the thigh revealed small but significant increases in non-bone lean tissue mass (p <
0.05 for time), with no difference between treatments (p = 0.37, treatment x time). Participants in the
lowest tertile of leg press strength at baseline had significantly less non-bone lean tissue in their thighs
compared with those in the upper tertiles (p < 0.05). However, the increases in non-bone lean tissue mass
of the thigh during the training period for participants in this lower tertile did not differ between treatments
(p = 0.85 treatment x time). Non-bone lean tissue mass in the thighs was strongly correlated with leg press
strength at baseline (r = 0.55, p < 0.001), but changes in thigh non-bone lean tissue mass by Week 12 were
not correlated with changes in leg press strength (r = 0.08, p = 0.63). Thigh girth increased during the
study period (p < 0.001 for time), but there was no significant treatment x time interaction (p = 0.72).

Protein levels and gene expression
The ratios of phosphorylated to non-phosphorylated protein, and mRNA expression data, are presented in
Table 5.
Table 5. Protein phosphorylation and mRNA expression. Values are mean (±SD).
CONT group (n = 10)
WGFE group (n = 10)
Week 0
Week 12
Week 0
Week 12
Pre-exercise
Post-exercise
Pre-exercise
Post-exercise
Pre-exercise
Post-exercise
Pre-exercise
Post-exercise
Phosphorylated to non-phosphorylated protein ratio
AKT1
1.00 (.00)
2.23 (2.58)
.91 (.61)
1.25 (1.00)
1.00 (.00)
1.62 (2.30)
1.89 (2.48)
.84 (1.20)
mTOR
1.00 (.00)
1.52 (.98)
1.14 (1.40)
2.61 (2.84)
1.00 (.00)
3.79 (4.99)
1.60 (1.56)
5.47 (4.75)*‡
s6k
p70
1.00 (.00)
4.86 (5.13)*
1.46 (1.24)
3.64 (4.42)
1.00 (.00)
2.50 (2.09)
.78 (.50)
4.95 (3.16)
FOXO3a
1.00 (.00)
1.04 (1.03)
1.64 (1.89)
1.31 (1.20)
1.00 (.00)
.94 (.38)
.97 (.25)
1.16 (.81)
mRNA expression
IGF-1Ea mRNA
1.00 (.00)
.77 (.56)
.96 (.52)
.78 (.31)
1.00 (.00)
1.21 (1.02)
1.40 (.49)
.98 (.76)
Atrogin-1 mRNA
1.00 (.00)
.60 (.54)
1.07 (.51)
.41 (.24)
1.00 (.00)
.57 (.41)
1.58 (1.24)†
.80 (.60)‡
MHC I mRNA
1.00 (.00)
1.14 (.56)
1.28 (1.06)
1.13 (.94)
1.00 (.00)
1.37 (.66)
1.50 (.94)
.95 (.79)
MHC IIa mRNA
1.00 (.00)
1.01 (.48)
.87 (.48)
.95 (.82)
1.00 (.00)
1.27 (.84)
1.48 (1.14)
.86 (.35)
MHC IIx mRNA
1.00 (.00)
1.16 (1.58)
1.10 (2.27)
.48 (.39)
1.00 (.00)
1.00 (.67)
1.48 (1.76)
.94 (.91)
CONT = Control, WGFE = Whey Growth Factor Extract.
*significantly different from Week 0 pre-exercise
†significantly different from Week 0 pre-exercise.
‡significantly different from Week 12 pre-exercise.

The only differences in treatment effects on protein phosphorylation ratios were for mTOR and p70s6k. At
Week 12 there was no difference in pre-exercise mTOR protein phosphorylation ratios between treatments
(p = 0.51), but mTOR phosphorylation increased significantly post-exercise in the WGFE group (p < 0.01)
but not CONT. In addition there was a large increase in p70s6k protein phosphorylation post-exercise at
Week 0 in CONT (385.9%, p = 0.04), but no significant change in the WGFE group.
In relation to effects on mRNA expression, in the WGFE group pre-exercise Atrogin-1 gene expression
levels at Week 12 were significantly higher than at Week 0 (p < 0.05) and decreased significantly from
pre- to post-exercise (-49.7%, p = 0.03). No such changes were evident in CONT.
Dietary intake
There were no differences in energy or macronutrient intake between groups at baseline (p > 0.17, Table
6). Energy intake, protein intake and carbohydrate intakes decreased during the study period (p < 0.02),
but with no difference between groups (p > 0.18 treatment x time). Fat intake did not change (p = 0.32).
Table 6. Daily energy and macronutrient intakes. Values are mean (±SD).
CONT group (n = 24)
WGFE group (n = 22)
Week 0
Week 6
Week 12
Week 0
Week 6
Week 12
Energy Intake, Kcal
2747(884)
2317(645)
9.3 (3.8)
2222(908)
2891(669)
2317(478)
Protein Intake, g
133(45)
114(45)
105(55)
123(31)
127(30)
108(25)
Fat Intake, g
109(50)
89(33)
97(64)
104(28)
112(34)
91(29)
Carbohydrate Intake, g
279(99)
245(102)
219(80)
325(107)
313(89)
252(54)

DISCUSSION
The main finding of the present study was that supplementation with 1.6 g/day of WGFE during 12 weeks
of resistance training in resistance-trained young men did not enhance increases in muscle strength or lean
tissue mass. Although there was a large increase (i.e. 34%) in the primary outcome of incline leg press
strength across the 12-week training program, strength improvements were similar in both treatment
groups and thus independent of WGFE supplementation.
The magnitude of increase (% increase from baseline) in incline leg press strength in the present study was
only ~25-30% of the increase reported in the previous study in untrained men (Carey et al., 2006;
Crittenden et al., 2009) which found that WGFE promoted greater increases in strength. It is well
established that the magnitude of training adaptations are contingent upon training status, and that the

gains in muscular strength that can be achieved decline with increased training experience (Peterson et al.,
2005), so it was not unexpected that the magnitude of strength increase in the present study would be
smaller. However, in the present study there was no evidence of WGFE enhancing strength increases as
had been reported previously in untrained men (Carey et al., 2006; Crittenden et al., 2009). This may have
been due to the lower dose of 1.6 g/day used in the present study compared with the 2 g/day dose used in
the previous study. Interestingly though, there was an inverse relationship between leg press strength at
baseline and the strength increase in the WGFE treatment group that was not apparent in CONT,
indicating that individuals taking WGFE who were less strong at baseline achieved larger gains than
stronger individuals. Secondary analysis of the leg press data comparing effects of WGFE and control
across tertiles of baseline leg press strength revealed that in the lowest tertile, participants who consumed
WGFE achieved greater strength increases than those who consumed CONT. This finding is consistent
with that of our earlier study (Crittenden et al., 2009) which reported greater increases in strength with
WGFE in untrained novices in so far as individuals with lower levels of strength, who may be less welltrained and therefore more similar to novices, appear to benefit from WGFE supplementation while bettertrained individuals do not. Thus, WGFE supplementation appears to provide no additional benefit for
experienced lifters who are already reasonably strong, but may provide benefits for less strong or novice
lifters.
Anthropometric and body composition changes in this study were small and did not differ between
treatment groups. Despite the small magnitude of whole body mass changes in this study, the changes
detected were primarily the result of increases in non-bone lean tissue. These non-bone lean tissue mass
increases, in combination with the small increases observed in thigh girth, suggest that skeletal muscle
hypertrophy was induced by the training undertaken, but there was no additional benefit of WGFE
supplementation. The increases in body weight and non-bone lean tissue mass were achieved despite
decreases in energy, protein and carbohydrate intakes during the study in both groups. The reduction in
dietary intake might have been a result of the daily supplementation with 20 g of whey protein in both
treatment groups as whey protein increases satiety and suppresses food intake compared with
carbohydrates or other proteins (Luhovyy et al., 2007).
Control of skeletal muscle hypertrophy and atrophy resides, in part, within the mTOR and the ubiquitinproteasome pathways respectively (Glass, 2005). Increased phosphorylation and activation of the effector
kinase, p70s6k, which interacts with the ribosomal protein S6, was measured within 3 hours of the
resistance exercise bouts. This is consistent with previous studies demonstrating rapid activation with
resistance exercise, particularly with the ingestion of supplemental whey protein (Burke et al., 2012;
Farnfield et al., 2009). However, WGFE supplementation did not significantly alter the response, either at
the first exercise session or at the end of the intervention period. Upstream of p70s6k, the phosphorylation
of the Ser2448 residue of mTOR tended to increase with exercise only with WGFE supplementation. It is
not clear what impact this phosphorylation site has on the kinase activity of mTOR, with the suggestion
that this is a feedback inhibitory phosphorylation site. There was no activation of FOXO3a
phosphorylation, consistent with previous studies demonstrating either suppressed or unchanged
phosphorylation in the first few hours after resistance exercise (Stefanetti et al., 2014). Correspondingly
there was a tendency for Atrogin-1 mRNA to be suppressed post-exercise, with no significant treatment
effect. Collectively, these signalling and molecular data, plus analysis of the expression of MHC genes,
fail to demonstrate a significant action of WGFE on either hypertrophic or atrogenic cellular pathways.
CONCLUSION
Supplementation with 1.6 g/day of WGFE during resistance exercise training might provide an advantage
for increasing strength in untrained individuals (i.e. novices) or individuals who are less well-adapted to

training, but not for individuals who are already well adapted to strength training.
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